Currently, ex vivo-generated CD4+ iTregs [154,155,156] and tolDCs [28,157] are being transferred into patients affected by diverse autoimmune diseases (multiple sclerosis, type I diabetes...) in clinical trials to test their therapeutic efficacy (Figure 5). Here, CD4 is linked to autoimmune disease.